Brain–computer interface relieves chronic chemotherapy‐induced peripheral neuropathy: A randomized, double‐blind, placebo‐controlled trial

Author:

Prinsloo Sarah12ORCID,Kaptchuk Ted J.3,De Ridder Dirk4,Lyle Randall5,Bruera Eduardo1ORCID,Novy Diane6ORCID,Barcenas Carlos H.7,Cohen Lorenzo G.1ORCID

Affiliation:

1. Department of Palliative, Rehabilitation, and Integrative Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Neurosurgery The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA

4. Section of Neurosurgery Department of Surgical Sciences University of Otago Dunedin New Zealand

5. Mount Mercy University Cedar Rapids Iowa USA

6. Department of Pain Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA

7. Breast Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA

Abstract

AbstractBackgroundChemotherapy‐induced peripheral neuropathy (CIPN) includes negative sensations that remain a major chronic problem for cancer survivors. Previous research demonstrated that neurofeedback (a closed‐loop brain–computer interface [BCI]) was effective at treating CIPN versus a waitlist control (WLC). The authors' a priori hypothesis was that BCI would be superior to placebo feedback (placebo control [PLC]) and to WLC in alleviating CIPN and that changes in brain activity would predict symptom report.MethodsRandomization to one of three conditions occurred between November 2014 and November 2018. Breast cancer survivors no longer in treatment were assessed at baseline, at the end of 20 treatment sessions, and 1 month later. Auditory and visual rewards were given over 20 sessions based on each patient's ability to modify their own electroencephalographic signals. The Pain Quality Assessment Scale (PQAS) at the end of treatment was the primary outcome, and changes in electroencephalographic signals and 1‐month data also were examined.ResultsThe BCI and PLC groups reported significant symptom reduction. The BCI group demonstrated larger effect size differences from the WLC group than the PLC group (mean change score: BCI vs. WLC, −2.60 vs. 0.38; 95% confidence interval, −3.67, −1.46 [p = .000; effect size, 1.07]; PLC, −2.26; 95% confidence interval, −3.33, −1.19 [p = .001 vs. WLC; effect size, 0.9]). At 1 month, symptoms continued to improve only for the BCI group. Targeted brain changes at the end of treatment predicted symptoms at 1 month for the BCI group only.ConclusionsBCI is a promising treatment for CIPN and may have a longer lasting effect than placebo (nonspecific BCI), which is an important consideration for long‐term symptom relief. Although scientifically interesting, the ability to separate real from placebo treatment may not be as important as understanding the placebo effects differently from effects of the intervention.Plain Language Summary Chemotherapy‐induced nerve pain (neuropathy) can be disabling for cancer survivors; however, the way symptoms are felt depends on how the brain interprets the signals from nerves in the body. We determined that the perception of neuropathy can be changed by working directly with the brain. Survivors in our trial played 20 sessions of a type of video game that was designed to change the way the brain processed sensation and movement. In this, our second trial, we again observed significant improvement in symptoms that lasted after the treatment was complete.

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3